[Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].

Abstract

Primary effusion lymphoma (PEL) is a rare B-cell lymphoma, characterized by human herpes virus 8 (HHV8) infection and serous effusions without detectable tumor masses. However, cases with HHV8 unrelated PEL have also been reported, mainly in Japan, and these are referred to as PEL-like lymphoma (PEL-LL). We describe a 70-year-old man with cardiac comorbidity who developed PEL-LL with pleural effusion. The patient achieved a complete response (CR) after treatment with oral low-dose sobuzoxane and etoposide combined with rituximab. To date, the patient has been in CR for about 7 months without chemotherapy. PEL-LL reportedly has a better prognosis than PEL. Because PEL-LL is positive for CD20, unlike PEL, combination therapy including rituximab may be effective. PEL-LL mainly affects elderly people, so that further investigation of tolerable and effective regimens is required.

• Authors: Kosuke Toyoda, Yasunobu Abe, Mariko Tsuda, Shojiro Haji, Ilseung Choi, Youko Suehiro, Junichi Kiyasu, Koichi Ohshima, Naokuni Uike
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 55 Issue 7 Pg. 815-9 (Jul 2014) ISSN: 0485-1439 [Print] Japan
• PMID: 25098519 (Publication Type: Case Reports, Journal Article)

Chemical References

• Piperazines
• Rituximab
• Etoposide
• sobuzoxane

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Etoposide
• Herpesvirus 8, Human
• Humans
• Lymphoma
• Lymphoma, Primary Effusion
• Male
• Piperazines
• Rituximab